Avenue Therapeutics (ATXI) Reaches New 12-Month Low at $2.36

Avenue Therapeutics Inc (NASDAQ:ATXI)’s share price reached a new 52-week low during trading on Monday . The company traded as low as $2.36 and last traded at $2.36, with a volume of 22557 shares. The stock had previously closed at $2.43.

ATXI has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Avenue Therapeutics in a research report on Wednesday, August 15th. Oppenheimer initiated coverage on shares of Avenue Therapeutics in a research report on Thursday, July 12th. They set a “buy” rating and a $8.00 price target on the stock.

The stock has a market capitalization of $29.76 million, a P/E ratio of -1.36 and a beta of -1.17.

Avenue Therapeutics (NASDAQ:ATXI) last released its quarterly earnings results on Tuesday, August 14th. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.23. Equities analysts forecast that Avenue Therapeutics Inc will post -2.31 EPS for the current fiscal year.

Avenue Therapeutics Company Profile (NASDAQ:ATXI)

Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.

See Also: What is the NASDAQ?

Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply